This phase II trial aims to evaluate disease-free survival of patients with locally advanced HNSCC managed with primary surgical resection and adjuvant radiotherapy with or without cisplatin, with consideration to the influence of disruptive TP53 mutations. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.